ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma - Top-Institutions - MDSpire

ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma

  • By

  • Xiaohong Yi

  • Xianwen Zhang

  • Lijun Huang

  • Yuhui Chen

  • Maochun You

  • Hongyi Jia

  • Lefeng Hou

  • Chao Hu

  • Kun Huang

  • Yumei Wang

  • June 2, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Neuro-Oncology
    • Immunotherapy

  • #2

    Dana-Farber/Harvard Cancer Center
    Dana-Farber/Harvard Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Neuro-Oncology
    • Immunotherapy

  • #3

    Northwestern University
    Northwestern University

    Chicago, Illinois

    Key Differentiators

    • Oncology
    • Immunotherapy

  • #4

    Columbia University Medical Center
    Columbia University Medical Center

    New York, New York

    Key Differentiators

    • Oncology
    • Neuro-Oncology

  • #5

    Vanderbilt University Medical Center
    Vanderbilt University Medical Center

    Nashville, Tennessee

    Key Differentiators

    • Oncology
    • Immunotherapy

Original Source(s)

ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma

  • by Xiaohong Yi, Xianwen Zhang, Lijun Huang, Yuhui Chen, Maochun You, Hongyi Jia, Lefeng Hou, Chao Hu, Kun Huang, Yumei Wang

  • June 2, 2026

Related Content

Bibliometric analysis of exercise and cancer prognosis research: trends, thematic evolution, and global collaborations (2015–2024)

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

  • by

  • June 1, 2026

  • 5 min